Jewish Hospital/University of Louisville
Team Implants AbioCor
(LOUISVILLE) – A fifth patient
received an AbioCor® Implantable Replacement Heart through the
efforts of a Jewish Hospital/University of Louisville team led by
surgeons Laman Gray, M.D., and Rob Dowling, M.D. The procedure took
place January 22, 2003, and lasted about 10 hours. The patient is
currently in critical but stable condition. At the request of the
patient’s family, the patient’s name and other details
are not being released.
Another Jewish Hospital patient, who received an AbioCor
implant on January 7, 2003, continues to recover. The patient remains
in critical but stable condition.
Jewish Hospital officials and the physicians who performed
the procedures will not be available for further comment at this
time. Updates will be provided as significant changes in either
patients’ condition occur and at the request of the families.
The experimental procedure is the result of some 20
years of product research and development by ABIOMED, Inc., of Danvers,
Mass. Jewish Hospital and University of Louisville surgeons Gray
and Dowling began working with the company about four years ago.
During the years leading up to the human implants, the device was
validated in FDA approved animal trials. A team of nurses, perfusionists,
physician assistants, anesthesiologists and other support staff
also worked in the development of the device to learn how to care
Patients who are eligible to receive an AbioCor device
have a high probability of dying within 30 days without the device.
They are not candidates for other treatments, such as a heart transplants.
Acrobat Reader Required)